CClinicalTrials.gg
CompletedNCT06639906Updated Sep 15, 2026

Is Preoperative Prediction of Intra-Abdominal Adhesions Possible?

An observational study in Adhesions Abdominal and Surgery, sponsored by Manisa Celal Bayar University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Manisa Celal Bayar University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
56
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

In this study, it was aimed to evaluate the presence of intra-abdominal adhesion with biochemical markers before the operation, as well as to determine whether there is a relationship between the severity of adhesion and preoperative blood decorin and TGF β1 levels by examining intra-abdominal adhesions histopathologically.This study was conducted on patients who were hospitalized in the department of gynecology and obstetrics of our hospital between 14.01.2024 and 08.10.2024 with laparotomy or laparoscopic abdominal surgery planned for gynecological reasons and who had at least 1 previous cesarean section or a history of previous abdominal surgery (laparoscopy or laparotomy). will be made among patients.

The study is voluntary and patients who meet the appropriate criteria will be informed verbally and written consent will be obtained from the patients. Preoperative blood samples will be taken from each patient included in the study. Patients with no adhesions detected in the abdomen during the operation will constitute the control group, and patients with adhesions detected will constitute the study group. The number of patients is planned to be 26 patients in the case group and 28 patients in the control group. Tissue samples removed from detected intra-abdominal adhesions will be taken for histological examination. The tissue samples obtained will be subjected to routine light microscopy tissue monitoring and embedded in paraffin blocks, 5 micron sections will be taken with a microtome and will be examined with a light microscope after being stained with Hematoxylin Eosin. Adhesions detected intra-abdominally are according to the "peritoneal adhesion index" classification; It will be graded in 4 stages: 0: No adhesion, 1: Thin adhesions, blunt dissection, 2: Dense adhesions, sharp dissection, 3: Dense dense and vascularized adhesions, sharp dissection, injury that can be prevented with difficulty. Thanks to the grading of intra-abdominal adhesions, it will be possible to evaluate not only whether the parameters examined are predictive of intra-abdominal adhesions, but also which degree of adhesions they are more effective in predicting. Whether the presence of intra-abdominal adhesion is predictable will be determined by comparing the decorin and TGF β biomarker levels in preoperative blood samples with the decorin and TGF β immunohistochemistry results in the adhesion tissue.

02

Conditions studied

  • Adhesions Abdominal
  • Surgery

Keywords

  • Intraabdominal Adhesion
  • Decorin
  • TGF β1
  • Gynecological Abdominal Surgery
  • Prediction
03

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

Patients with Intraabdominal Adhesions

Inclusion criteria

  • Patients who are hospitalized for gynecological reasons with a planned laparotomy or laparoscopic abdominal surgery
  • Patients with at least 1 previous cesarean section or history of previous abdominal surgery (laparoscopy or laparotomy)

Exclusion criteria

Exclusion Criteria:

  • Patients who do not agree to participate in the study will not be included in the study.
  • Pregnant patients will not be included in the study (so that the physiological changes of pregnancy do not affect the results)
  • Presence of preoperative clinical or laboratory findings of infection (such as high fever, tachycardia, leukocytosis, high CRP)
  • Presence of hematological or coagulation disorders
  • History or presence of cancer treatment
  • History or presence of connective tissue disease
  • Presence of diabetes
  • Being under 18 years of age will be considered as exclusion criteria.
04

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
56 participants (actual)
Target follow-up
24 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 1:

    Patients with intra-abdominal adhesions

  • Group 2:
05

What researchers measure

Primary outcomes

  1. 1% Patients's intraabdominal adhesion tissues while surgery. Adhesion tissues Staining will be Measured by decorin and TGF β immunohistochemistry.

    Time frame: Baseline

  2. Patient's blood will measured by decorin and TGF β biochemistry technique.

    Time frame: Baseline

Secondary outcomes

  1. Sociodemographic questions were measured by survey technique.

    Time frame: Baseline

06

Study locations

1 site
  • Manisa Celal Bayar University
    Manisa, Turkey (Türkiye)
07

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06639906
Lead sponsor
Manisa Celal Bayar University
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Jan 14, 2024
Primary completion
Oct 8, 2024
Completion
Apr 1, 2026
Last update
Sep 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion